Year Founded
2015
Ownership
Private
Employees
~100
Therapeutic Areas
Stage
Commercial
Modalities
Strata Oncology General Information
Developed proprietary biomarker algorithms including Immunotherapy Response Score (IRS) and ADC Treatment Response Scores for predicting treatment benefit. Recently demonstrated utility of IRS in predicting pembrolizumab benefit in NSCLC patients.
Drug Pipeline
No pipeline data available
Key Partnerships
No partnerships listed
Strata Oncology Funding
Deal Type | Date | Amount | Status | Stage |
---|
To view Strata Oncology's complete valuation and funding history, request access »
Strata Oncology Investors
Notable investors not specifically named in search results but referenced as present on website/investors page.
Investor Type: Venture Capital
Holding: Minority